Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12302432 | 0.90 | MAPT (0.36) | MAPTALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL2452207 | 0.89 | IRAK1 (0.35) | MAPTALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL1703017 | 0.89 | IRAK1 (0.35) | MAPTALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL12302390 | 0.88 | MAPT (0.37) | MAPTALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL12302433 | 0.88 | ALDH1A1 (0.39) | MAPTALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL2452346 | 0.83 | MAPT (0.42) | MAPTALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL2448595 | 0.82 | AURKA (0.36) | MAPTALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL2452968 | 0.80 | IRAK1 (0.34) | MAPTALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL1703312 | 0.80 | IRAK1 (0.34) | MAPTALDH1A1TDP1KDM4EL3MBTL1 | |
| SCHEMBL16152431 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | disclosed |
| EP-2440528-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-8487103-B2 | Quinoline inhibitors of hepatitis C virus polymerase | ROCHE PALO ALTO LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-8487103-B2 | Quinoline inhibitors of hepatitis C virus polymerase | ROCHE PALO ALTO LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| WO-2010142656-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | disclosed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | MAPT 4670/4885ALDH1A1 1266/4885TDP1 2359/4885 |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, IRF3 | MAPT 4753/4885ALDH1A1 2014/4885TDP1 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.